cvi-hbv-002
Vaccineexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2014 (NCT02693652)
Timeline
Indications
Mechanism of action
- Hepatitis B virusImmunity, active
Hepatitis B virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cvi-hbv-002
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06147895 | Phase 1 | Aug 30, 2021 | CHA University, CHA Vaccine Institute Co., Ltd. |
| NCT04289987 | Phase 2 | Feb 19, 2020 | CHA Vaccine Institute Co., Ltd. |
| NCT02693652 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2014 | Cha Medical University, CHA Vaccine Institute Co., Ltd. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CHA Vaccine Institute Co., Ltd. | For profit | 3 | 3 | 2 | 2014 |
| Cha Medical University | Academic/Hospital | 1 | 0 | 1 | 2014 |
| CHA University | Academic/Hospital | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1